BriaCell Presents Clinical and Scientific Findings at the Annual Symposium of Society of Surgical Oncology 2020
August 17 2020 - 5:30AM
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”)
(TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology
company specializing in targeted immunotherapy for advanced breast
cancer, is announcing the results of clinical studies with its lead
product candidate, Bria-IMT™, summarized in a poster
session during the SSO 2020 International Conference on Surgical
Cancer Care™, a virtual event held in the evenings of August 17-18,
2020. The patient data summarized and discussed belong to
previously-disclosed patients (i.e., no incremental numbers
enrolled).
The poster describes clinical and
pharmacodynamic responses to Bria-IMT™ in combination with
pembrolizumab (KEYTRUDA®; manufactured by Merck & Co., Inc.), a
PD-1 inhibitor, from a phase I/IIa trial in 11 evaluable advanced
breast cancer patients. Our preliminary data showed that in these
very heavily pre-treated patients, robust immune activity was
associated with more pronounced tumor regression (i.e., a decrease
in the size of a tumor), and clinical benefit - including
progression free survival rates - in the advanced breast cancer
patients who were treated with Bria-IMT™ in combination with
KEYTRUDA®.
The poster is posted on
https://briacell.com/novel-technology/scientific-publications/.
The details of BriaCell’s SSO 2020 poster are as follows:
Presentation Title: Results of
a Phase I/IIa Trial of Combination Whole-Cell Targeted
Immunotherapy Vaccine and Checkpoint Inhibitor in Treatment of
Metastatic/Recurrent Breast CancerSession
Dates: August 17-18Session Time: 6pm
ET
Summarized Data:
- The patients were heavily
pre-treated having failed an average of 9 prior treatment agents
received.
- Of 11 patients in the study with
KEYTRUDA®, a pronounced tumor regression was observed in 2
patients.
- No serious side effects were
observed in the patients who were treated with the
combination.
- Immune system activation was
strongly correlated with clinical benefits in the patients who were
treated with the combination.
- The median of progression-free
survival was 183 days, suggesting clinical benefit of the treatment
in the patients.
In conclusion, no serious side effect was
observed in the 11 evaluable patients as a result of the treatment
with the Bria-IMT™ regimen with KEYTRUDA®. Additionally, our
preliminary data showed that the treatment regimen was able to
activate the immune system and induce potential anti-tumor immunity
in advanced breast cancer patients. Importantly, a robust immune
response appeared to be associated with clinical benefit and more
pronounced tumor regression in the patients, suggesting clinical
efficacy of the combination regimen in this heavily pre-treated
patient population. We have further studied the data of these
patients and have identified the patient population that may
benefit the most from this treatment regimen. We presented the data
recently at the AACR annual meeting.
About Cancer Insight
Founded in 2014, Cancer Insight, LLC, is a
Texas-based clinical research organization (CRO) dedicated to
discovering, developing and testing emerging biotechnologies
specializing in cancer immunotherapy. Cancer Insight offers a
vertical range of CRO services from trial design to final
execution, with a foundation grounded on decades of academic
research and clinical trial experience.
About the SSO 2020 International Conference on Surgical
Cancer Care™
Over the years, the SSO 2020 International
Conference on Surgical Cancer Care™ has become a meeting venue for
practitioners around the world to discuss and offer expertise on a
range of cancer related topics. This year, the SSO 2020
International Conference on Surgical Cancer Care™ will take place
as a virtual event the evenings of August 17th and 18th. The 2020
conference sessions are comprehensive in the range of topics and
the depth of expertise delivered. Management of Breast Cancer in
Women Age 70+ will be a focused conference section.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and effective approaches
for the management of cancer.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation (also
known as "forward-looking statements") which are subject to known
and unknown risks relevant to the Company in particular and to the
biotechnology and pharmaceutical industries in general,
uncertainties and other factors that may cause actual events to
differ materially from current expectation. These risks are more
fully described in the Company's public filings available at
www.sedar.com.
These forward-looking statements include, but
are not limited to, BriaCell’s plans, objectives, expectations and
intentions. Such forward-looking statements reflect BriaCell's
current beliefs and are based on information currently available to
management. Although the forward-looking statements contained in
this news release are based upon what BriaCell believes are
reasonable assumptions, there can be no assurance that actual
results will be consistent with these forward-looking
statements.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please contact:
BriaCell Therapeutics
Corp.:William V. Williams, MDPresident & CEOPhone:
1-888-485-6340
BriaCell Therapeutics
Corp.:Farrah DeanManager, Corporate DevelopmentEmail:
farrah@BriaCell.com Phone: 1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2023 to Apr 2024